HIV/AIDS Therapeutics Market to 2017 - Superior Combination Therapies and Decreasing Mortality to Sustain Market Growth Despite Major Patent Expiries

Discount offer till 6th April 2012


Summary

GBI Research, the leading business intelligence provider, has released its latest research, “HIV/AIDS Therapeutics Market to 2017 - Superior Combination Therapies and Decreasing Mortality to Sustain Market Growth Despite Major Patent Expiries”. It provides in-depth analysis of the unmet needs, drivers and barriers that affect the global HIV/AIDS therapeutics market. The report analyzes the markets for HIV/AIDS in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage pattern and annual cost of treatment are forecast until 2017 for key geographies in the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers and acquisitions (M&A) and licensing agreements that shape the global markets.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Scope

The scope of this report includes -
-Annualized market data for the HIV therapeutics market from 2002 to 2010, forecast until 2017.
-Analysis of the HIV therapeutics market in the leading geographies of the world: the US, the UK, Germany, France, Italy, Spain, and Japan.
-Market characterization of the HIV therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns.
-Key drivers and barriers that have a significant impact on the market.
-Coverage of pipeline molecules in various phases of drug development.
-Competitive benchmarking of leading companies. The key companies studied in this report are Gilead Sciences Inc, GlaxoSmithKline, Bristol-Myers Squibb, Abbott Laboratories, Merck & Co and Pfizer Inc.
-Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global HIV therapeutics market.

Reasons to buy

The report will assist business development and marketing executives to strategize their product launches, by allowing them to -
-Align product portfolio to the markets with high growth potential.
-Develop market entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
-Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety.
-Develop key strategic initiatives by understanding key focus areas of leading companies.
-Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

1.1 List of Tables
1.2 List of Figures
2 HIV/AIDS Therapeutics Market to 2017 - Introduction
2.1 GBI Research Report Guidance
3 HIV/AIDS Therapeutics Market to 2017 - Global Overview
3.1 Disease Overview
3.2 Market Overview
3.3 Overview of Recent Research Advancements in HIV/AIDS Therapy
4 HIV/AIDS Therapeutics Market to 2017 - Market Characterization
4.1 Market Forecasts
4.1.1 Branded Versus Generics
4.2 Annual Cost of Therapy
4.3 Treatment Usage Patterns
4.3.1 Diseased Population
4.3.2 Treatment Seeking Population
4.3.3 Diagnosis Population
4.3.4 Prescription Population
4.4 Geographical Distribution
4.5 Drivers and Restraints
4.6 Market Drivers
4.6.1 Increase in Awareness Levels of Disease Progression will Lead to an Increase in Treatment Seeking and Diagnosed Populations
4.6.2 New Product Launches will Increase Uptake and Drive the Market
4.6.3 Increase in Drug Prices will Drive Growth and Lessen the Impact of Generics
4.7 Market Restraints
4.7.1 Patent Expirations and the Subsequent Entry of Generics will Negatively Impact the Market
4.7.2 Social Stigma Associated with HIV Leads to Low Treatment Seeking Rate
4.7.3 Rigorous and Complex Treatment Regimes Result in Poor Patient Compliance Leading to a Reduction in Drug Volumes
5 HIV/AIDS Therapeutics Market to 2017 - The US
5.1 Market Forecasts
5.2 Annual Cost of Therapy
5.3 Treatment Usage Patterns
5.3.1 Diseased Population
5.3.2 Treatment Seeking Population
5.3.3 Diagnosis Population
5.3.4 Prescription Population
6 HIV/AIDS Therapeutics Market to 2017- Top Five European Countries
6.1 Market Forecasts
6.1.1 Revenue by Country
6.2 Annual Cost of Therapy
6.3 Treatment Usage Patterns
6.3.1 Diseased Population
6.3.2 Treatment Seeking Population
6.3.3 Diagnosis Population
6.3.4 Prescription Population
7 HIV/AIDS Therapeutics Market to 2017 - Japan
7.1 Market Forecasts
7.2 Annual Cost of Therapy
7.3 Treatment Usage Patterns
7.3.1 Diseased Population
7.3.2 Treatment Seeking Population
7.3.3 Diagnosis Population
7.3.4 Prescription Population
8 HIV/AIDS Therapeutics Market to 2017 - Pipeline Assessment
8.1 Major Classes of Drugs
8.1.1 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
8.1.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
8.1.3 Protease Inhibitors
8.1.4 Viral Fusion (or Entry) Inhibitors
8.1.5 HIV Integrase Strand Transfer Inhibitors
8.1.6 Multi-Class Combination Products
8.2 Pipeline Overview
8.3 Strategic Pipeline Assessment
8.4 HIV/AIDS Therapeutics Pipeline - Pipeline by Clinical Phases of Development
8.4.1 HIV/AIDS Therapeutics - Phase III Clinical Pipeline
8.4.2 HIV/AIDS Therapeutics - Phase II Clinical Pipeline
8.4.3 HIV/AIDS Therapeutics - Phase I Clinical Pipeline
8.4.4 HIV/AIDS - Preclinical Pipeline
8.4.5 HIV/AIDS - Discovery Clinical Pipeline
8.5 HIV/AIDS Therapeutics - Pipeline by Mechanism of Action
8.6 HIV/AIDS Therapeutics - Most Promising Drugs under Clinical Development
9 HIV/AIDS Therapeutics Market to 2017 - Competitive Landscape
9.1 Major Company Profiles
9.1.1 Gilead Sciences, Inc
9.1.2 GlaxoSmithKline (GSK)
9.1.3 Bristol-Myers Squibb (BMS)
9.1.4 Abbott Laboratories
9.1.5 Merck
9.1.6 Pfizer
10 HIV/AIDS Therapeutics Market to 2017 - Licencing and Partnership Deals
10.1 Global HIV/AIDS Market
10.1.1 Overview: Deals by Type and Geography
10.1.2 Mergers and Acquisitions
10.1.3 Licensing Agreements
11 HIV/AIDS Therapeutics Market to 2017 - Appendix
11.1 Market Definitions
11.2 Abbreviations
11.3 Research Methodology
11.3.1 Coverage
11.3.2 Secondary Research
11.3.3 Primary Research
11.3.4 Forecasts
11.3.5 Expert Panel Validation
11.4 Contact Us
11.5 Disclaimer
11.6 Sources

List of Tables

Table 1: HIV/AIDS Therapeutics Market, Global, Revenue ($m), 2002-2010
Table 2: HIV/AIDS Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017
Table 3: HIV/AIDS Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010
Table 4: HIV/AIDS Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017
Table 5: HIV/AIDS Therapeutics Market, Global, Treatment Usage Patterns (‘000), 2002-2010
Table 6: HIV/AIDS Therapeutics Market, Global, Treatment Usage Patterns (‘000), 2010-2017
Table 7: HIV/AIDS Therapeutics Market, Global, Diseased Population (‘000), 2002-2010
Table 8: HIV/AIDS Therapeutics Market, Global, Diseased Population (‘000), 2010-2017
Table 9: HIV/AIDS Therapeutics Market, Global, Treatment Seeking Population (‘000), 2002-2010
Table 10: HIV/AIDS Therapeutics Market, Global, Treatment Seeking Population (‘000), 2010-2017
Table 11: HIV/AIDS Therapeutics Market, Global, Diagnosis Population, 2002-2010
Table 12: HIV/AIDS Therapeutics Market, Global, Diagnosis Population, 2010-2017
Table 13: HIV/AIDS Therapeutics Market, Global, Prescription Population, 2002-2010
Table 14: HIV/AIDS Therapeutics Market, Global, Prescription Population, 2010-2017
Table 15: HIV/AIDS Therapeutics Market, Global, Geographical Distribution of Revenues ($m), 2002-2010
Table 16: HIV/AIDS Therapeutics Market, Global, Geographical Distribution of Revenues ($m), 2010-2017
Table 17: HIV/AIDS Therapeutics Market, Global, Key Drugs Going Off Patent, 2009-2017
Table 18: HIV/AIDS Therapeutics Market, the US, Revenues ($m), 2002-2010
Table 19: HIV/AIDS Therapeutics Market, the US, Revenue ($m), 2010-2017
Table 20: HIV/AIDS Therapeutics Market, the US, Annual Cost of Therapy ($), 2002-2010
Table 21: HIV/AIDS Therapeutics Market, the US, Annual Cost of Therapy ($), 2010-2017
Table 22: HIV/AIDS Therapeutics Market, the US, Treatment Usage Patterns (‘000), 2002-2010
Table 23: HIV/AIDS Therapeutics Market, US, Treatment Usage Patterns (‘000), 2010-2017
Table 24: HIV/AIDS Therapeutics Market, the US, Diseased Population (‘000), 2002-2010
Table 25: HIV/AIDS Therapeutics Market, the US, Diseased Population (‘000), 2010-2017
Table 26: HIV/AIDS Therapeutics Market, the US, Treatment Seeking Population (‘000), 2002-2010
Table 27: HIV/AIDS Therapeutics Market, the US, Treatment Seeking Population (‘000), 2010-2017
Table 28: HIV/AIDS Therapeutics Market, US, Diagnosis Population (‘000), 2002-2010
Table 29: HIV/AIDS Therapeutics Market, US, Diagnosis Population (‘000), 2010-2017
Table 30: HIV/AIDS Therapeutics Market, the US, Prescription Population (‘000), 2002-2010
Table 31: HIV/AIDS Therapeutics Market, the US, Prescription Population (‘000), 2010-2017
Table 32: HIV/AIDS Therapeutics Market, Top Five European Countries, Revenues ($m), 2002-2010
Table 33: HIV/AIDS Therapeutics Market, Top Five European Countries, Revenues ($m), 2010-2017
Table 34: HIV/AIDS Therapeutics Market, Top Five European Countries, Revenue by Country ($m), 2002-2010
Table 35: HIV/AIDS Therapeutics Market, Top Five European Countries, Revenue by Country ($m), 2010-2017
Table 36: HIV/AIDS Therapeutics Market, Top Five European Countries, Annual Cost of Therapy ($), 2002-2010
Table 37: HIV/AIDS Therapeutics Market, Top Five European Countries, Annual Cost of Therapy ($), 2010-2017
Table 38: HIV/AIDS Therapeutics Market, Top Five European Countries, Treatment Usage Patterns, 2002-2010
Table 39: HIV/AIDS Therapeutics Market, Top Five European Countries, Treatment Usage Patterns, 2010-2017
Table 40: HIV/AIDS Therapeutics Market, Top Five European Countries, Diseased Population (’000), 2002-2010
Table 41: HIV/AIDS Therapeutics Market, Top Five European Countries, Diseased Population (’000), 2010-2017
Table 42: HIV/AIDS Therapeutics Market, Top Five European Countries, Treatment Seeking Population (’000), 2002-2010
Table 43: HIV/AIDS Therapeutics Market, Top Five European Countries, Treatment Seeking Population (’000), 2010-2017
Table 44: HIV/AIDS Therapeutics Market, Top Five European Countries, Diagnosis Population (’000), 2002-2010
Table 45: HIV/AIDS Therapeutics Market, Top Five European Countries, Diagnosis Population (’000), 2010-2017
Table 46: HIV/AIDS Therapeutics Market, Top Five European Countries, Prescription Population (’000), 2002-2010
Table 47: HIV/AIDS Therapeutics Market, Top Five European Countries, Prescription Population (’000), 2010-2017
Table 48: HIV/AIDS Therapeutics Market, Japan, Revenues ($m), 2002-2010
Table 49: HIV/AIDS Therapeutics Market, Japan, Revenues ($m), 2010-2017
Table 50: HIV/AIDS Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2010
Table 51: HIV/AIDS Therapeutics Market, Japan, Annual Cost of Therapy ($), 2010-2017
Table 52: HIV/AIDS Therapeutics Market, Japan, Treatment Usage Patterns (‘000), 2002-2010
Table 53: HIV/AIDS Therapeutics Market, Japan, Treatment Usage Patterns (‘000), 2010-2017
Table 54: HIV/AIDS Therapeutics Market, Japan, Diseased Population (’000), 2002-2010
Table 55: HIV/AIDS Therapeutics Market, Japan, Diseased Population (’000), 2010-2017
Table 56: HIV/AIDS Therapeutics Market, Japan, Treatment Seeking Population (’000), 2002-2010
Table 57: HIV/AIDS Therapeutics Market, Japan, Treatment Seeking Population (’000), 2010-2017
Table 58: HIV/AIDS Therapeutics Market, Japan, Diagnosis Population (’000), 2002-2010
Table 59: HIV/AIDS Therapeutics Market, Japan, Diagnosis Population (’000), 2010-2017
Table 60: HIV/AIDS Therapeutics Market, Japan, Prescription Population (’000), 2002-2010
Table 61: HIV/AIDS Therapeutics Market, Japan, Prescription Population (’000), 2010-2017
Table 62: HIV/AIDS Therapeutics Market, Global, Different Classes of Drugs
Table 63: HIV/AIDS Therapeutics Market, Phase III Pipeline, 2010
Table 64: HIV/AIDS Therapeutics Market, Phase II Pipeline, 2010
Table 65: HIV/AIDS Therapeutics Market, Phase I Pipeline, 2010
Table 66: HIV/AIDS Therapeutics Market, Preclinical Pipeline, 2010
Table 67: HIV/AIDS Therapeutics Market, Discovery Clinical Pipeline, 2010
Table 68: HIV/AIDS Therapeutics Market, Most Promising Drugs Under Clinical Development, 2010
Table 69: HIV/AIDS Therapeutics Market, Global, Benchmarking Analysis for Top Three Companies, 2010
Table 70: HIV/AIDS Therapeutics Market, Global, Licensing Agreements for Drugs in the Preclinical Stage, 2009
Table 71: HIV/AIDS Therapeutics Market, Global, Licensing Agreements for Drugs in Phase II, 2009
Table 72: HIV/AIDS Therapeutics Market, Global, Licensing Agreements for Drugs in Phase III, 2009
Table 73: HIV/AIDS Therapeutics Market, Global, Licensing Agreements for Approved Drugs, 2009

List of Figures

Figure 1: HIV/AIDS Therapeutics Market, Global, HIV Treatment Flow Algorithm, 2011
Figure 2: HIV/AIDS Therapeutics Market, Global, Market Overview, 2010
Figure 3: HIV/AIDS Therapeutics Market, Global, Revenue ($m), 2002-2017
Figure 4: HIV/AIDS Therapeutics Market, Global, Revenue Segmentation, 2010-2017
Figure 5: HIV/AIDS Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017
Figure 6: HIV/AIDS Therapeutics Market, Global, Treatment Usage Patterns, 2002-2017
Figure 7: HIV/AIDS Therapeutics Market, Global, Diseased Population, 2002-2017
Figure 8: HIV/AIDS Therapeutics Market, Global, Treatment Seeking Population, 2002-2017
Figure 9: HIV/AIDS Therapeutics Market, Global, Diagnosis Population, 2002-2017
Figure 10: HIV/AIDS Therapeutics Market, Global, Prescription Population, 2002-2017
Figure 11: HIV/AIDS Therapeutics Market, Global, Geographical Distribution of Revenues ($m), 2002-2017
Figure 12: HIV/AIDS Therapeutics Market, the US, Revenue ($m), 2002-2017
Figure 13: HIV/AIDS Therapeutics Market, the US, Annual Cost of Therapy ($), 2002-2017
Figure 14: HIV/AIDS Therapeutics Market, the US, Treatment Usage Patterns, 2002-2017
Figure 15: HIV/AIDS Therapeutics Market, the US, Diseased Population, 2002-2017
Figure 16: HIV/AIDS Therapeutics Market, the US, Treatment Seeking Population, 2002-2017
Figure 17: HIV/AIDS Therapeutics Market, US, Diagnosis Population, 2002-2017
Figure 18: HIV/AIDS Therapeutics Market, the US, Prescription Population, 2002-2017
Figure 19: HIV/AIDS Therapeutics Market, Top Five European Countries, Revenue ($m), 2002-2017
Figure 20: HIV/AIDS Therapeutics Market, Top Five European Countries, Revenue by Country ($m), 2002-2017
Figure 21: HIV/AIDS Therapeutics Market, Top Five European Countries, Annual Cost of Therapy ($), 2002-2017
Figure 22: HIV/AIDS Therapeutics Market, Top Five European Countries, Treatment Usage Patterns, 2002-2017
Figure 23: HIV/AIDS Therapeutics Market, Top Five European Countries, Diseased Population, 2002-2017
Figure 24: HIV/AIDS Therapeutics Market, Top Five European Countries, Treatment Seeking Population, 2002-2017
Figure 25: HIV/AIDS Therapeutics Market, Top Five European Countries, Diagnosis Population, 2002-2017
Figure 26: HIV/AIDS Therapeutics Market, Top Five European Countries, Prescription Population, 2002-2017
Figure 27: HIV/AIDS Therapeutics Market, Japan, Revenue ($m), 2002-2017
Figure 28: HIV/AIDS Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2017
Figure 29: HIV/AIDS Therapeutics Market, Japan, Treatment Usage Patterns, 2002-2017
Figure 30: HIV/AIDS Therapeutics Market, Japan, Diseased Population, 2002-2017
Figure 31: HIV/AIDS Therapeutics Market, Japan, Treatment Seeking Population, 2002-2017
Figure 32: HIV/AIDS Therapeutics Market, Japan, Diagnosis Population, 2002-2017
Figure 33: HIV/AIDS Therapeutics Market, Japan, Prescription Population, 2002-2017
Figure 34: HIV/AIDS Therapeutics Market, Pipeline by Phases of Development (%), 2010
Figure 35: HIV/AIDS Therapeutics Market, Pipeline by Mechanism of Action (%), 2010
Figure 36: HIV/AIDS Therapeutics Market, Global, Competitive Analysis of Major Manufacturers, Revenues, 2008-2010
Figure 37: HIV/AIDS Therapeutics Market, Gilead, HIV Revenue as Percentage of Total Revenue, 2010
Figure 38: HIV/AIDS Therapeutics Market, Gliead Sciences Ic, SWOT Analysis, 2010
Figure 39: HIV/AIDS Therapeutics Market, GlaxoSmithKline, HIV Revenue as Percentage of Total Revenue, 2010
Figure 40: HIV/AIDS Therapeutics Market, GlaxoSmithKline, SWOT Analysis, 2010
Figure 41: HIV/AIDS Therapeutics Market, Bristol-Myers-Squibb, HIV Revenue as Percentage of Total Revenue, 2010
Figure 42: HIV/AIDS Therapeutics Market, Bristol-Myers Squibb, SWOT Analysis, 2010
Figure 43: HIV/AIDS Therapeutics Market, Abbott, HIV Revenue as Percentage of Total Revenue, 2010
Figure 44: HIV/AIDS Therapeutics Market, Abbott Laboratories, SWOT Analysis, 2010
Figure 45: HIV/AIDS Therapeutics Market, Merck, HIV Revenue as Percentage of Total Revenue, 2010
Figure 46: HIV/AIDS Therapeutics Market, Merck, SWOT Analysis, 2010
Figure 47: HIV/AIDS Therapeutics Market, Pfizer, SWOT Analysis, 2010
Figure 48: HIV/AIDS Therapeutics Market, Global, Deals by Geography and Type, 2009-2010
Figure 49: HIV/AIDS Therapeutics Market, Global, M&A Deals, 2009-2010
Figure 50: HIV/AIDS Therapeutics Market, Global, Major Licensing Agreements by Phase, 2009-2010
Figure 51: GBI Research Market Forecasting Model